In CRC, tumoral expression of the membrane-bound receptor form of PD-L1 (mPD-L1) is a rare characteristic strongly associated with PD-1-positive lymphocytic infiltrates and deficiency in mismatch-repair systems, which are markers predicting high immunogenicity and responsiveness to anti-PD-1/PD-L1 therapies [52]. This evidence concerns the gene CD274 and colorectal carcinoma.